Literature DB >> 8049254

The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors.

P Y Gasdaska1, J E Oblong, I A Cotgreave, G Powis.   

Abstract

The cDNA sequences of thioredoxin obtained by PCR cloning from human colon cancer cells, human lymphoblastoid cells, and human liver have been found to be identical with the cDNA sequence reported for the autocrine growth factor, human adult T-cell leukemia derived factor (ADF). Recombinant human thioredoxin was 95% reduced by dithiothreitol and was a substrate for reduction by human thioredoxin reductase. Human non-small cell primary lung tumors from subjects who were not cigarette smokers at the time of surgery showed significantly increased levels of thioredoxin mRNA compared to thioredoxin mRNA in paired normal human lung tissue. Subjects who were smokers did not show a significant increase in lung tumor thioredoxin mRNA. The results of the study show that human thioredoxin and ADF are identical species and suggest that there may be increased production of thioredoxin (ADF) by some human cancers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049254     DOI: 10.1016/0167-4781(94)90180-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  19 in total

Review 1.  The mitochondrial component of intracrine action.

Authors:  Richard N Re; Julia L Cook
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-09       Impact factor: 4.733

Review 2.  Thiol chemistry in peroxidase catalysis and redox signaling.

Authors:  Alberto Bindoli; Jon M Fukuto; Henry Jay Forman
Journal:  Antioxid Redox Signal       Date:  2008-09       Impact factor: 8.401

3.  Two members of the thioredoxin-h family interact with the kinase domain of a Brassica S locus receptor kinase.

Authors:  M S Bower; D D Matias; E Fernandes-Carvalho; M Mazzurco; T Gu; S J Rothstein; D R Goring
Journal:  Plant Cell       Date:  1996-09       Impact factor: 11.277

4.  A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers.

Authors:  A F Baker; T Dragovich; K N Adab; N Raghunand; Hhs Chow; S P Stratton; S W Squire; M Boice; L A Pestano; D L Kirkpatrick
Journal:  Invest New Drugs       Date:  2012-06-19       Impact factor: 3.850

5.  Growth promoting effect of thioredoxin on intestinal epithelial cells.

Authors:  Shigeo Takaishi; Mitsutaka Sawada; Hiroshi Seno; Takahisa Kayahara; Yukari Morita-Fujisawa; Hiroaki Fukuzawa; Tsutomu Chiba
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

6.  Nuclear expression of thioredoxin-1 in the invasion front is associated with outcome in patients with gallbladder carcinoma.

Authors:  Motoaki Nagano; Kinta Hatakeyama; Masahiro Kai; Hajime Nakamura; Junji Yodoi; Yujiro Asada; Kazuo Chijiiwa
Journal:  HPB (Oxford)       Date:  2012-06-08       Impact factor: 3.647

7.  Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.

Authors:  Garth Powis; Peter Wipf; Stephen M Lynch; Anne Birmingham; D Lynn Kirkpatrick
Journal:  Mol Cancer Ther       Date:  2006-03       Impact factor: 6.261

Review 8.  Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling.

Authors:  Eva-Maria Hanschmann; José Rodrigo Godoy; Carsten Berndt; Christoph Hudemann; Christopher Horst Lillig
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

Review 9.  Redox regulation of cell survival by the thioredoxin superfamily: an implication of redox gene therapy in the heart.

Authors:  Md Kaimul Ahsan; Istvan Lekli; Diptarka Ray; Junji Yodoi; Dipak K Das
Journal:  Antioxid Redox Signal       Date:  2009-11       Impact factor: 8.401

10.  Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence.

Authors:  Jae Yun Lim; Sun Och Yoon; Soon Won Hong; Jong Won Kim; Seung Ho Choi; Jae Yong Cho
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.